Hepatitis C is een levervirus van welk de infectie
meestal in een chronische infectie resulteert. Recent zijn nieuwe
antivirale middelen ontwikkeld die het virus bij het merendeel
van de patiënten kunnen uitroeien. Natuurlijke remedies missen
echter dezelfde onderzoeksinteresse die voor farmaca bestaat.
Terecht, omdat (fyto)nutriënten weinig invloed hebben op het
virus zelf. Onterecht, omdat ze extra kansen bieden om
levercomplicaties te voorkomen.
Beste bezoeker, u heeft geen toegang.
Enkel (web)abonnees hebben toegang tot tijdschriftartikelen. Het webabonnement is nog in de maak.
U kunt zich wel alvast (gratis) registreren en tal van andere webartikelen raadplegen!
Auteur
Verschenen in
Referenties
Graham CS, Swan T. A path to eradication of hepatitis C in low- and middle-income countries. Antiviral Res. 2015 Jul;119:89-96. doi: 10.1016/j.antiviral.2015.01.004
Wang CC, Hsu CS, Liu CJ et al. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol. 2008 May;23(5):779-82
Modaresi Esfeh J, Ansari-Gilani K. Steatosis and hepatitis C. Gastroenterol Rep (Oxf). 2015 Aug 13. pii: gov040
Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011 Sep;26(9):1361-7
Olubamwo OO, Onyeka IN, Miettola J, Kauhanen J, Tuomainen TP. Hepatitis C as a risk factor for carotid atherosclerosis - a systematic review. Clin Physiol Funct Imaging. 2015 Jan 26. doi: 10.1111/cpf.12229
Jou JH, Muir AJ. In the clinic. Hepatitis C. Ann Intern Med. 2012 Dec 4;157(11):ITC6-1 – ITC6-16
Nyalakonda H, Utay NS. A new era of therapy for hepatitis C virus infection. Curr Opin Infect Dis. 2015 Oct;28(5):471-478
Kudo M. Tailor-Made Therapy for viral hepatitis: Recent advances. Digestion 2011;84(suppl 1):1-4
Liu Q, Bengmark S, Qu S. Nutrigenomics therapy of hepatisis C virus induced-hepatosteatosis. BMC Gastroenterol. 2010 May 20;10:49
Abd El-Kader SM, Al-Jiffri OH, Al-Shreef FM et al. Liver enzymes and psychological well-being response to aerobic exercise training in patients with chronic hepatitis C. Afr Health Sci. 2014 Jun;14(2):414-9
Huisman EJ, van Meer S, van Hoek B et al. Effects of preventive versus "on-demand" nutritional support on paid labour productivity, physical exercise and performance status during PEG-interferon-containing treatment for hepatitis C. Clin Res Hepatol Gastroenterol. 2015 Jul 15. pii: S2210-7401(15)00140-0
Pattullo V, Duarte-Rojo A, Soliman W et al. A 24-week dietary and physical activity lifestyle intervention reduces hepatic insulin resistance in the obese with chronic hepatitis C. Liver Int. 2013 Mar;33(3):410-9
Payen JL, Pillard F, Mascarell V et al. Is physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavirin therapy? Gastroenterol Clin Biol. 2009 Jan;33(1 Pt 1):8-14
Thomas CH, Lok ASF, Locarnini SA (Ed.) Viral hepatitis (2014) Wiley Blackwell, 4th Ed.
Freire TO, Boulhosa RS, Oliveira LP et al. n-3 polyunsaturated fatty acid supplementation reduces insulin resistance in hepatitis C virus infected patients: a randomised controlled trial. J Hum Nutr Diet. 2015 Jul 27. doi: 10.1111/jhn.12327
Himoto T, Yoneyama H, Kurokohchi K et al. Selenium deficiency is associated with insulin resistance in patients with hepatitis C virus-related chronic liver disease. Nutr Res. 2011 Nov;31(11):829-35
Modi AA, Feld JJ, Park Y et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010 Jan;51(1):201-9
Khalaf N, White D, Kanwal F1 et al. Coffee and caffeine are associated with decreased risk of advanced hepatic fibrosis among patients with hepatitis C. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1521-1531.e3
Cardin R, Piciocchi M, Martines D et al. Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial. Dig Liver Dis. 2013 Jun;45(6):499-504
Singal AK, Jampana SC, Weinman SA. Antioxidants as therapeutic agents for liver disease. Liver Int. 2011 Nov;31(10):1432-48
Takagi H, Kakizaki S, Sohara N, Sato K et al. Pilot clinical trial of the use of alpha-tocopherol for the prevention of hepatocellular carcinoma in patients with liver cirrhosis. Int J Vitam Nutr Res. 2003 Nov;73(6):411-5
Farias MS, Budni P, Ribeiro CM et al. Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients. Gastroenterol Hepatol. 2012 Jun-Jul;35(6):386-94
Groenbaek K, Friis H, Hansen M et al. The effect of antioxidant supplementation on hepatitis C viral load, transaminases and oxidative status: a randomized trial among chronic hepatitis C virus-infected patients. Eur J Gastroenterol Hepatol. 2006 Sep;18(9):985-9
Melhem A, Stern M, Shibolet O et al. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol. 2005 Sep;39(8):737-42
Beloqui O, Prieto J, Suárez M et al. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res. 1993 Aug;13(4):279-82
Grant PR, Black A, Garcia N et al. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study. J Med Virol. 2000 Aug;61(4):439-42
Neri S, Ierna D, Antoci S et al. Association of alpha-interferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva Med. 2000 Sep;42(3):187-92
Lin CC, Yin MC. et al. Vitamins B depletion, lower iron status and decreased antioxidative defense in patients with chronic hepatitis C treated by pegylated interferon alfa and ribavirin. Clin Nutr. 2009 Feb;28(1):34-8
Lin CC, Liu WH, Wang ZH, Yin MC. Vitamins B status and antioxidative defense in patients with chronic hepatitis B or hepatitis C virus infection. Eur J Nutr. 2011 Oct;50(7):499-506
Rocco A1, Compare D, Coccoli P et al. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut. 2013 May;62(5):766-73
Malaguarnera M, Vacante M, Bertino G et al. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin. J Interferon Cytokine Res. 2011 Sep;31(9):653-9
Malaguarnera G, Pennisi M, Gagliano C et al. Acetyl-L-carnitine supplementation during HCV therapy with pegylated interferon-α 2b plus ribavirin: effect on work performance; a randomized clinical trial. Hepat Mon. 2014 May 5;14(5):e11608
Romano M, Vacante M, Cristaldi E et al. L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. Dig Dis Sci. 2008 Apr;53(4):1114-21
Malaguarnera M, Vacante M, Giordano M et al. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol. 2011 Oct 21;17(39):4414-20
Tarao K, Fujiyama S, Ohkawa S et al. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):164-9
Niederau C, Strohmeyer G, Heintges T et al. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group. Hepatogastroenterology. 1998 May-Jun;45(21):797-804
Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. Med Klin (Munich). 1999 Oct 15;94 Suppl 3:84-9
Berkson BM. Alpha Lipoic Acid and Liver Disease. Townsend Lett. 2007 dec. http://www.townsendletter.com/Dec2007/alphalipo1207.htm
Ridruejo E, Castiglioni T, Silva MO. Thioctic acid-induced acute cholestatic hepatitis. Ann Pharmacother. 2011 Jul;45(7-8):e43
Mendes PR, Félix Ddos S, Silva PC et al. Effect of alpha lipoic acid on the blood cell count and iron kinetics in hypertensive patients. Nutr Hosp. 2014 Nov 3;31(2):883-9
Nagamine T, Takagi H, Takayama H et al. Preliminary study of combination therapy with interferon-alpha and zinc in chronic hepatitis C patients with genotype 1b. Biol Trace Elem Res. 2000 Summer;75(1-3):53-63
Takagi H, Nagamine T, Abe T, Takayama H et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepat. 2001 Sep;8(5):367-71
Matsuoka S, Matsumura H, Nakamura H et al. Zinc supplementation improves the outcome of chronic hepatitis C and liver cirrhosis. J Clin Biochem Nutr. 2009 Nov;45(3):292-303
Matsumura H, Nirei K, Nakamura H et al. Zinc supplementation therapy improves the outcome of patients with chronic hepatitis C. J Clin Biochem Nutr. 2012 Nov;51(3):178-84
Abbasinazari M, Alavian SM, Behnava B et al. Effect of zinc supplementation on viral response in patients with chronic hepatitis C and Beta thalassemia major, a pilot study. J Clin Diagn Res. 2014 Dec;8(12):HC16-9
Steinbrenner H, Al-Quraishy S, Dkhil MA, Wunderlich F, Sies H. Dietary selenium in adjuvant therapy of viral and bacterial infections. Adv Nutr. 2015 Jan 15;6(1):73-82
Carreño V. Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy. Aliment Pharmacol Ther. 2014 Jan;39(2):148-62
Kato J, Miyanishi K, Kobune M et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol. 2007 Oct;42(10):830-6
Bares JM, Berger J, Nelson JE et al. Silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C. J Clin Gastroenterol. 2008 Sep;42(8):937-44
Yang Z, Zhuang L, Lu Y et al. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. Biomed Res Int. 2014;2014:941085
Mayer KE, Myers RP, Lee SS. Silymarin treatment of viral hepatitis: a systematic review. J Viral Hepat. 2005 Nov;12(6):559-67
Yang Z, Zhuang L, Lu Y et al. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials. Biomed Res Int. 2014;2014:941085
Biermer M, Schlosser B, Fülöp B et al. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. J Viral Hepat. 2012 Aug;19(8):547-53
Braun DL, Rauch A, Aouri M, Durisch N et al. A lead-in with silibinin prior to triple-therapy translates into favorable treatment outcomes in difficult-to-treat HIV/hepatitis C coinfected patients. PLoS One. 2015 Jul 15;10(7):e0133028
Braun DL, Rauch A, Durisch N et al. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients. HIV Med. 2014 Nov;15(10):625-30
Wei F, Liu SK, Liu XY et al. Meta-analysis: silymarin and its combination therapy for the treatment of chronic hepatitis B. Eur J Clin Microbiol Infect Dis. 2013 May;32(5):657-69
Ikeda K, Arase Y, Kobayashi M et al. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig Dis Sci. 2006 Mar;51(3):603-9
Fujioka T, Kondou T, Fukuhara A et al. Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis C: a pilot study. Hepatol Res. 2003 May;26(1):10-14
Stern E. Two cases of hepatitis C treated with herbs and supplements. J Altern Complement Med. 1997 Spring;3(1):77-82
Kainuma M, Hayashi J, Sakai S et al. The efficacy of herbal medicine (kampo) in reducing the adverse effects of IFN-beta in chronic hepatitis C. Am J Chin Med. 2002;30(2-3):355-67
Deng G, Kurtz RC, Vickers A et al. A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-sai-ko-to or xiao-chai-hu-tang) in chronic hepatitis C patients. J Ethnopharmacol. 2011 Jun 14;136(1):83-7
Barakat EM, El Wakeel LM, Hagag RS. Effects of Nigella sativa on outcome of hepatitis C in Egypt. World J Gastroenterol. 2013 Apr 28;19(16):2529-36
Shikov AN, Djachuk GI, Sergeev DV et al. Birch bark extract as therapy for chronic hepatitis C--a pilot study. Phytomedicine. 2011 Jul 15;18(10):807-10
Azocar J, Diaz A. Efficacy and safety of Chlorella supplementation in adults with chronic hepatitis C virus infection. World J Gastroenterol. 2013 Feb 21;19(7):1085-90
Yakoot M, Salem A. Spirulina platensis versus silymarin in the treatment of chronic hepatitis C virus infection. A pilot randomized, comparative clinical trial. BMC Gastroenterol. 2012 Apr 12;12:32
Huber R, Müller M, Naumann J et al. Artichoke leave extract for chronic hepatitis C - a pilot study. Phytomedicine. 2009 Sep;16(9):801-4
Hampton T. Grapefruit compound battles hepatitis C. JAMA. 2008 Apr 2;299(13):1532
Morcos PN, Brennan B, Smith PF. A grapefruit a day for patients infected with hepatitis C? Hepatology. 2008 Jun;47(6):2141-2; author reply 2142-3
Halegoua-De Marzio D, Kraft WK et al. Limited sampling estimates of epigallocatechin gallate exposures in cirrhotic and noncirrhotic patients with hepatitis C after single oral doses of green tea extract. Clin Ther. 2012 Dec;34(12):2279-2285.e1
Calland N, Dubuisson J, Rouillé Y et al. Hepatitis C virus and natural compounds: a new antiviral approach? Viruses. 2012 Oct 17;4(10):2197-217
Nakamura M, Saito H, Ikeda M et al. An antioxidant resveratrol significantly enhanced replication of hepatitis C virus. World J Gastroenterol. 2010 Jan 14;16(2):184-92
Mazzanti G, Di Sotto A, Vitalone A. Hepatotoxicity of green tea: an update. Arch Toxicol. 2015 Aug;89(8):1175-91
Whitsett M, Marzio DH, Rossi S. SlimQuick™-associated hepatotoxicity resulting in fulminant liver failure and orthotopic liver transplantation. ACG Case Rep J. 2014 Jul 8;1(4):220-2